ICH Culture: Its Maintenance and Development
| Autor: | Tatsuo Kurokawa, Hironobu Saito, Masafumi Yokota, Akira Kawahara |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Value (ethics)
business.industry Public Health Environmental and Occupational Health Globe Pharmacy Public relations Transparency (behavior) Globalization Grassroots medicine.anatomical_structure medicine Pharmacology (medical) business Objectivity (science) Pharmacology Toxicology and Pharmaceutics (miscellaneous) Pharmaceutical industry |
| Zdroj: | Therapeutic Innovation & Regulatory Science. 51:9-10 |
| ISSN: | 2168-4804 2168-4790 |
| DOI: | 10.1177/2168479016665877 |
| Popis: | The founding industry members (European Federation of Pharmaceutical Industries and Associations [EFPIA], Japanese Pharmaceutical Manufacturers Association [JPMA], and Pharmaceutical Research and Manufacturers of America [PhRMA]) of the International Council for Harmonisation (ICH) have a 25-year track record of the contribution to ICH. Given that further globalization of ICH is expected, we should value this legacy and maintain the current ICH culture and its principles of "benefit to the patients first" and "science-based approach," through which industry members would ensure transparency and objectivity in their ICH activities. In order to maintain and develop the culture of the ICH and its current momentum, a 2-way approach is important: (1) sharing common views through dialogues among leaders of each industry association, such as through the Industry Executive Council, and (2) spreading the values through grassroots activities involving wider stakeholders in global forums such as DIA, as platforms for sharing the knowledge, views, and culture of ICH across the globe. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink